The Filing Desk

Rigel Pharmaceuticals

RIGL · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

RIGL · Last close · November 13, 2026
$44.46
Value Rigel Pharmaceuticals yourself

Rigel Pharmaceuticals' revenue rose 64.2% to $294 million in fiscal 2025. Its operating margin was 42.6%, up from 13.5% a year earlier. The diluted share count rose 6.5%.

RIGEL PHARMACEUTICALS INC Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001034842-26-000015 Updated
Revenue
$294M
64.2%
Operating margin
42.6%
29.1 pts
Net income
$367M
1999.1%
Free cash flow
—
 
Return on capital
91.3%
 
Market cap
$907M
Nov 13 close
P/E
2.8x
On $16.07 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-10), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Rigel Pharmaceuticals does

Rigel Pharmaceuticals develops and sells drugs for blood disorders and cancer. It has three FDA-approved products. TAVALISSE treats adults with chronic immune thrombocytopenia (ITP), a condition with low platelet counts, when an earlier treatment did not work well enough. REZLIDHIA treats adults with relapsed or refractory acute myeloid leukemia with a specific IDH1 mutation. GAVRETO, which Rigel began selling in June 2024, treats certain lung and thyroid cancers driven by a RET gene change.

Rigel earns money from net sales of these three medicines, mostly in the United States. TAVALISSE is also sold in Europe, the United Kingdom, Japan, Korea, Canada and Israel. It in-licensed REZLIDHIA from Forma Therapeutics, now part of Novo Nordisk, and bought the US rights to GAVRETO from Blueprint Medicines, now part of Sanofi. Rigel also receives payments from partners.

Its pipeline includes R289, a drug being tested in patients with lower-risk myelodysplastic syndrome, a group of bone marrow disorders. It is also testing olutasidenib with research partners in other diseases with IDH1 mutations. Eli Lilly leads a program for a third drug, an RIPK1 inhibitor.

Its biggest risks, as it describes them

  • Its three approved products may sell less than it expects, or the markets may be smaller than it believes.
  • Drug discovery and development often fail to produce successful product candidates.
  • Generic versions of its products, or of competing products, could hurt its business.
  • Difficulty managing growth and the risks of buying or in-licensing other drugs or companies.
  • Changes in US healthcare laws and policies, and strict regulation of the drug industry.
From Rigel Pharmaceuticals's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2024 to 2025, earnings per share grew 1,867.7% a year and net income 1,997.1% a year, as new shares raised the share count by 6% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments125585777155
Debt incl. finance leases2040606052
Net debt (negative means net cash)−105−183−17−102
Net debt to EBITDA———−0.7x−0.8x
Debt to equity0.7x———0.1x
Interest coverage−2.6x−15.0x−3.0x3.1x17.1x
Current ratio2.4x1.8x1.9x2.1x2.4x
Quick ratio2.3x1.6x1.8x2.0x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Rigel Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Rigel Pharmaceuticals says to expect

  • Full year 2026: total revenuesUpdated 2026 Outlook: Total revenues of approximately $290 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $260 million and contract revenues from collaborations of approximately $35 million
  • Full year 2026: net incomeThe company also continues to anticipate it will report positive net income for the full year 2026, while funding existing and new clinical development programs.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Rigel Pharmaceuticals reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 97 of 97 of 9
Rule of 40———
Altman Z''−37.95−23.750.31
Accruals ratio−15.4%−9.9%86.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positiveFailPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsFailPassPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassPassPass
F-score4 of 97 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Rigel Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Rigel PharmaceuticalsFY2564.2%42.6%—91.3%−0.8x7
Ironwood PharmaceuticalsFY25−15.7%33.3%42.9%———Compare
Xeris BiopharmaFY2543.7%8.5%—19.6%4.2x7Compare
EvolusFY2511.6%−11.0%−15.4%−47.2%—2Compare
Aurinia PharmaceuticalsFY2520.4%37.1%47.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2044459109149120117179294
Revenue growth—−78.0%892.6%33.2%83.2%37.4%−19.4%−2.8%53.4%64.2%
Gross profit——4458108148118110161275
Research and development63464753606560242333
Operating income−70−80−73−69−29−12−56−2024126
Net income−69−78−70−67−30−18−59−2518367
Diluted EPS (US$)−7.30−6.20−4.40−4.00−1.80−1.10−3.44−1.440.9919.48
Diluted shares (millions)9131617171717171819
Cash flow
Cash from operations−76−78−59−42−526−74−63276
Capital expenditure1012110———
Free cash flow−77−78−60−43−535−74———
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation76897101291213
Balance sheet at fiscal year end
Cash and short-term investments751161289857125585777155
Debt incl. finance leases———10202040606052
Total assets78119139148110167134117164514
Total liabilities2318299476137148146161122
Shareholders' equity55101110543430−14−293392
Margins and ratios
Gross margin——99.4%98.5%99.2%99.3%98.5%93.9%89.6%93.3%
Operating margin−342.1%−1,775.6%−163.3%−116.5%−26.7%−8.4%−46.2%−17.5%13.5%42.6%
Net margin−339.6%−1,739.3%−158.3%−112.8%−27.4%−12.0%−48.7%−21.5%9.8%124.7%
Free cash flow margin−376.3%−1,733.3%−134.7%−72.5%−49.2%3.5%−61.7%———
Rule of 40 (growth + FCF margin)—−1,811.3%758.0%−39.3%34.0%40.9%−81.1%———
Return on capital—————————91.3%
Return on equity−94.5%−100.2%−67.0%−81.7%−67.7%−55.6%−699.0%——185.9%
Return on assets−66.0%−79.1%−54.6%−46.7%−23.1%−12.9%−38.8%−19.9%12.4%108.3%
Net debt to EBITDA————————−0.7x−0.8x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Rigel Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Rigel Pharmaceuticals.